01.05.16
OncoMed Pharmaceuticals achieved two milestones from Celgene Corp. totaling $70 million based on analysis of Phase Ib and interim Phase II clinical trial safety data associated with the demcizumab (anti-DLL4, OMP-21M18) program.
The data from the pancreatic, non-small cell lung and ovarian cancer clinical trials showed no demcizumab-related Grade 3 or higher cardio-pulmonary toxicities among 155 patients treated. Of those, 68 patients have received at least two cycles of demcizumab at the Phase II dose or higher and have been followed for at least 100 days.
OncoMed also earned a $2.5 million milestone for clinical candidate designation of an undisclosed preclinical immuno-oncology program. This is OncoMed’s second immuno-oncology program to reach clinical candidate designation, and both programs are advancing in IND-enabling studies.
“The achievement of the demcizumab $70 million safety milestone is based on extensive Phase Ib and blinded Phase II data, and positions OncoMed to rapidly enroll its Phase II randomized YOSEMITE and DENALI clinical trials, as well as the Phase Ib demcizumab plus pembrolizumab (anti-PD1) trial, and also to explore the potential of demcizumab in ovarian cancer,” said Paul J. Hastings, OncoMed’s chairman and chief executive officer.
The data from the pancreatic, non-small cell lung and ovarian cancer clinical trials showed no demcizumab-related Grade 3 or higher cardio-pulmonary toxicities among 155 patients treated. Of those, 68 patients have received at least two cycles of demcizumab at the Phase II dose or higher and have been followed for at least 100 days.
OncoMed also earned a $2.5 million milestone for clinical candidate designation of an undisclosed preclinical immuno-oncology program. This is OncoMed’s second immuno-oncology program to reach clinical candidate designation, and both programs are advancing in IND-enabling studies.
“The achievement of the demcizumab $70 million safety milestone is based on extensive Phase Ib and blinded Phase II data, and positions OncoMed to rapidly enroll its Phase II randomized YOSEMITE and DENALI clinical trials, as well as the Phase Ib demcizumab plus pembrolizumab (anti-PD1) trial, and also to explore the potential of demcizumab in ovarian cancer,” said Paul J. Hastings, OncoMed’s chairman and chief executive officer.